Novo Nordisk said it would work with ChatGPT maker OpenAI on how to leverage artificial intelligence to discover new drugs, the latest AI partnership in the medical field as healthcare companies seek ...

Novo Nordisk is partnering with OpenAI to "bring new and better treatment options to patients faster," the Danish drugmaker said Tuesday. "Integrating AI in our everyday work gives us the ability to ...

OpenAI published a substantial update to GPT-Rosalind on June 3, 2026, deepening the domain-specialized model's performance across drug discovery, genomics, and wet-lab research — and opening the ...